• leader board size
Top Stories2020-11-19T07:53:47-08:00

Breaking News

Compass Builds a Commercial Case for COMP360

NEW YORK – Compass Pathways is advancing COMP360, its proprietary synthetic psilocybin for treatment-resistant depression (TRD), through a rolling FDA New Drug Application, with a commercial launch targeted for H1 2027. Alongside the regulatory push, ...

Subscribe To Our Newsletter

Go to Top